- Home
- PDX vs ARDX Comparison
PDX vs ARDX Comparison
Compare PDX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- ARDX
- Stock Information
- Founded
- PDX 2019
- ARDX 2007
- Country
- PDX NY
- ARDX United States
- Employees
- PDX N/A
- ARDX N/A
- Industry
- PDX Finance/Investors Services
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- PDX Finance
- ARDX Health Care
- Exchange
- PDX Nasdaq
- ARDX Nasdaq
- Market Cap
- PDX 1.1B
- ARDX 971.4M
- IPO Year
- PDX N/A
- ARDX 2014
- Fundamental
- Price
- PDX $23.25
- ARDX $3.67
- Analyst Decision
- PDX
- ARDX Strong Buy
- Analyst Count
- PDX 0
- ARDX 8
- Target Price
- PDX N/A
- ARDX $10.19
- AVG Volume (30 Days)
- PDX N/A
- ARDX 6.4M
- Earning Date
- PDX 01-01-0001
- ARDX 07-31-2025
- Dividend Yield
- PDX 4.95%
- ARDX N/A
- EPS Growth
- PDX N/A
- ARDX N/A
- EPS
- PDX N/A
- ARDX N/A
- Revenue
- PDX N/A
- ARDX $361,706,000.00
- Revenue This Year
- PDX N/A
- ARDX $12.67
- Revenue Next Year
- PDX N/A
- ARDX $32.07
- P/E Ratio
- PDX N/A
- ARDX N/A
- Revenue Growth
- PDX N/A
- ARDX 127.33
- 52 Week Low
- PDX $13.52
- ARDX $3.21
- 52 Week High
- PDX $21.05
- ARDX $8.06
- Technical
- Relative Strength Index (RSI)
- PDX 62.68
- ARDX 39.95
- Support Level
- PDX $21.85
- ARDX $3.86
- Resistance Level
- PDX $23.35
- ARDX $4.06
- Average True Range (ATR)
- PDX 0.55
- ARDX 0.23
- MACD
- PDX 0.13
- ARDX 0.04
- Stochastic Oscillator
- PDX 93.92
- ARDX 43.40
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.